Back to profile profile_subnav_contactperson - PJ (Paul) Wichgers Schreur MSc type_page Antigen discovery and presentation Wageningen Bioveterinary Research (WBVR) is involved in vaccine development projects for specific pathogens in close collaboration with public and... Rift Valley fever Rift Valley fever (RVF) is a viral zoonosis that primarily affects animals but also has the capacity to infect humans. Wageningen Bioveterinary... Crimean Congo haemorrhagic fever Crimean Congo haemorrhagic fever virus (CCHFV) is a bunya virus transmitted from animals to humans via ticks. In humans, the virus can cause serious... News Promising first results in human clinical trial of Rift Valley fever vaccine 30 juli 2024 | Promising first results in human clinical trial of Rift Valley fever vaccine - WUR News Promising first results in human clinical trial of Rift Valley... WBVR awarded with 25 million CEPI grant for Rift Valley fever vaccine research 10 oktober 2023 | The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its partnership with Wageningen Bioveterinary Research (WBVR, part of... Novel Rift Valley fever vaccine dosed in Phase I human trial 18 augustus 2022 | The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA... New vaccine against Rift Valley fever is safe and effective in pregnant sheep 27 januari 2021 | A study by Wageningen Bioveterinary Research (WBVR), in collaboration with BunyaVax and Ceva Animal Health, shows that a new live-attenuated candidate... Synthetic antibodies built with bacterial superglue could help fight emerging viruses 29 april 2020 | Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in... 12Next